Norway · Delayed Price · Currency is NOK Photocure ASA Company Description
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products.
It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer.
It also develops Cevira for the treatment of human papilloma virus-induced cervical precancerous lesions.
The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira; and a strategic agreement with Richard Wolf GmbH to develop and commercialize a 4K LED high-definition reusable blue light cystoscope based on Richard Wolf’s System blue technology.
It sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners.
The company operates in the Nordic countries, Germany, France, Austria, the United Kingdom, the Benelux, Italy, rest of the Europe, Canada, and the United States.
Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.
| Country | Norway |
| Founded | 1993 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 101 |
| CEO | Daniel Schneider |
Contact Details
Address: Hoffsveien 4 Oslo, 0275 Norway | |
| Phone | 47 22 06 22 10 |
| Website | photocure.com |
Stock Details
| Ticker Symbol | PHO |
| Exchange | Oslo Børs |
| Fiscal Year | January - December |
| Reporting Currency | NOK |
| ISIN Number | NO0010000045 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Daniel Schneider | President and Chief Executive Officer |
| Erik Dahl | Chief Financial Officer |
| Anja Gossens-von der Heidt | Head of Global Human Resources |
| Dr. Anders Neijber M.D. | Chief Medical Officer of Global Medical Affairs, Clinical Development and Research & Development |
| David Moskowitz | Head of Investor Relations |
| Tolv Hillestad | Group Controller |